Drugs / DGX-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05121831 | Feb → Nov 2022 | depressive disorder | Digestome Therapeutics | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DGX-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05121831 ↗ |
| Modality | Peptide | “DGX-001 is a peptide being investigated for the treatment of the major depressive disorder.” NCT05121831 ↗ |